Home > Boards > Free Zone > Penny Fundamentals > Pinto Beans and Money Making Stock Picks 2019 (BEAN)

(ADMP) MC $33 M-FDA DECISION ON Oct.31...the most

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ADVFN_bioking Member Profile
 
Followed By 13
Posts 439
Boards Moderated 12
Alias Born 05/15/17
160x600 placeholder
ADVFN_bioking   Monday, 10/21/19 10:50:40 AM
Re: None
Post # of 186977 
(ADMP) MC $33 M-FDA DECISION ON Oct.31...the most underpriced and hottest fda play for the year .. they have already a marketed drug partnered with Sanodz (Novartis) which targeting a $1.5 BILLION market the drug was full lauchned in Q2 this year = POTENTIAL 10 BAGGER HERE GUYS ..


Admamis Pharma (ADMP)

Market-Cap:$33 million
Cash: $17 million
Price: $0.54


Presentation
http://ir.adamispharmaceuticals.com/static-files/63eff6dd-0286-457e-a959-920540f0cdb1



ZIMHI (naloxone) injection

Indication–Opioid Overdose

Addressable Market -$330 million

FDA action date Oct. 31, 2019




SYMJEPI (epinephrine) injection

Indication-Anaphylaxis

Addressable Market -$1.5 billion

Launched–January 2019


First products using patented, FDA-approved injection device
Both doses (0.3mg and 0.15mg) are FDA approved

Sandoz a division of Novartis –commercial partner in U.S.

Commercial deal terms –50% of net profits, upfront fee and potential performance-based milestone payments




Near-Term Target Milestones

FDA action date (PDUFA) of Oct. 31, 2019 on NDA for ZIMHI

Pursuing potential partnerships for SYMJEPI (ex-US) and ZIMHI product candidate

Continued launch of SYMJEPI in U.S. –retail and SYMJEPI low dose launches pending

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist